false 0001029125 0001029125 2022-05-12 2022-05-12
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM 8-K
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
May 12, 2022
Date of Report (Date of Earliest Event Reported)
 
 
Panbela Therapeutics, Inc
(Exact Name of Registrant as Specified in its Charter)
 
 
Delaware
  
001-39468
  
87-0543922
(State of Incorporation)
  
(Commission File Number)
  
(I.R.S. Employer Identification No.)
 
 
712 Vista Blvd #305
Waconia, Minnesota
  
55387
(Address of Principal Executive Offices)
  
(Zip Code)
 
 
(952) 479-1196
(Registrant’s Telephone Number, Including Area Code)
 
 
(Former Name or Former Address, if Changed Since Last Report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
  
Trading Symbol
  
Name of each exchange on which registered
Common Stock, $0.001 par value
  
PBLA
  
The Nasdaq Stock Market LLC
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 
 
 
Item 2.02.         Results of Operations and Financial Condition.
 
On May 12, 2022, Panbela Therapeutics, Inc. (the “Company”) issued a press release providing a business update and announcing financial results for the first quarter ended March 31, 2022. The full text of the press release is set forth in Exhibit 99.1 attached hereto and is incorporated by reference in this current report on Form 8-K as if fully set forth herein.
 
The Company is furnishing the information contained in this report, including Exhibit 99.1, pursuant to Item 2.02 of Form 8-K promulgated by the Securities and Exchange Commission (the “SEC”). This information shall not be deemed to be “filed” with the SEC for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
 
Item 9.01.         Financial Statements and Exhibits.
 
(d)         Exhibits
 
Exhibit No.
  
Description
  
Method of Filing
99.1
    
Furnished Herewith
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)    
   
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.
 
PANBELA THERAPEUTICS, INC.
Date: May 12, 2022
By
/s/ Susan Horvath
Susan Horvath
Chief Financial Officer
 
 
Panbela Therapeutics (NASDAQ:PBLA)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Panbela Therapeutics Charts.
Panbela Therapeutics (NASDAQ:PBLA)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Panbela Therapeutics Charts.